
Zhitong Finance App News, Nuochengjianhua (09969) issued an announcement. According to the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (Health Insurance (2026) No. 29) (hereinafter referred to as the “National Health Insurance Catalogue”) issued by the National Health Security Administration and the Ministry of Human Resources and Social Security, Nuochengjianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) independently developed by Nuochengjianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) was included in the new national medical insurance catalogue (trade name: Enoxin®, hereinafter referred to as “zoletrantinib”), for therapeutic carrying Adult and adolescent solid tumor patients aged 12 and over with the NTRK fusion gene. The new version of the National Health Insurance Catalogue will be officially implemented from January 1, 2027.
Zoletritinib is a next-generation pan-TRK inhibitor independently developed by the company to treat advanced or metastatic solid tumor patients with NTRK fusion genes who have not been treated with TRK inhibitors and are resistant to first-generation TRK inhibitors. Zoletritinib not only provides long-term deep relief, but also has strong brain penetrating activity and good overall safety. At the same time, data shows that it can overcome the resistance of first-generation TRK inhibitors. Zolectinib is taken orally once a day, bringing great convenience to patients.
In key registered clinical trials on solid tumor patients positive for NTRK gene fusion, zoletriptinib demonstrated excellent efficacy and safety. The results of the registered clinical study showed an overall response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, a 24-month progression-free survival (PFS) rate of 77.4%, and a 24-month overall survival (OS) rate of 90.8%.
In December 2025, zoletriptinib was approved to treat solid tumor patients in adults and adolescents over 12 years of age carrying the NTRK fusion gene. This is the first new-generation TRK inhibitor independently developed and approved for marketing in China, marking an important breakthrough in the field of broad-spectrum anti-cancer drug research and development in China.
Currently, the marketing application for zoletrinib to treat pediatric oncology patients (2 to 12 years old) has been accepted and included in the priority review. It has also been included in the “Pediatric Antineoplastic Drug Research and Development Encouragement Pilot Program (Starlight Program)”.
This time, zoletrantinib was included in the national health insurance catalogue, reflecting the recognition by the National Health Insurance Administration of the clinical value, innovative properties, and patient benefits of innovative drugs. This product is suitable for adults carrying the NTRK fusion gene and young solid cancer patients aged 12 and above. After being included in the national medical insurance catalogue, it is beneficial to reduce patients' out-of-pocket burden, enhance patient accessibility, and have a positive impact on the company's long-term business development. The company will actively cooperate with the implementation of local health insurance policies and is committed to benefiting more patients.